c.i. 42510 has been researched along with Colitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aboutouk, FH; Amin, NA; El-Galeel, YA; El-Hefnawy, A; El-Shedody, R; El-Zoghby, G; Gobba, NA; Khalifa, A; Osama, D; Saber, S; Saleh, RA; Shabaka, D; Sharaf, H; Youssef, ME | 1 |
| Buongusto, F; Castelo-Branco, MT; Coutinho-Silva, R; de Souza, HS; do Rosário, A; Marques, CC; Pacheco, RG; Schanaider, A | 1 |
2 other study(ies) available for c.i. 42510 and Colitis
| Article | Year |
|---|---|
BBG enhances OLT1177-induced NLRP3 inflammasome inactivation by targeting P2X7R/NLRP3 and MyD88/NF-κB signaling in DSS-induced colitis in rats.
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Cytokines; Dextran Sulfate; Inflammasomes; Interleukin-18; Interleukin-1beta; Male; Myeloid Differentiation Factor 88; NF-kappa B; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Wistar; Receptors, Purinergic P2X7; Rosaniline Dyes; Signal Transduction | 2021 |
Prophylactic systemic P2X7 receptor blockade prevents experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Colitis; Collagen; Colon; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Goblet Cells; Injections, Intraperitoneal; Macrophages; Male; NF-kappa B; Peroxidase; Purinergic P2X Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P2X7; Rosaniline Dyes; T-Lymphocytes; Trinitrobenzenesulfonic Acid | 2014 |